KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) FCF Margin (2016 - 2025)

Historic FCF Margin for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to 31.73%.

  • Pacira BioSciences' FCF Margin rose 21700.0% to 31.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.33%, marking a year-over-year decrease of 105200.0%. This contributed to the annual value of 25.5% for FY2024, which is 48400.0% up from last year.
  • Per Pacira BioSciences' latest filing, its FCF Margin stood at 31.73% for Q3 2025, which was up 21700.0% from 5.14% recorded in Q2 2025.
  • In the past 5 years, Pacira BioSciences' FCF Margin registered a high of 36.96% during Q3 2021, and its lowest value of 0.83% during Q1 2021.
  • In the last 5 years, Pacira BioSciences' FCF Margin had a median value of 21.25% in 2022 and averaged 19.25%.
  • Its FCF Margin has fluctuated over the past 5 years, first surged by 469300bps in 2021, then tumbled by -238700bps in 2025.
  • Over the past 5 years, Pacira BioSciences' FCF Margin (Quarter) stood at 8.83% in 2021, then soared by 141bps to 21.25% in 2022, then increased by 19bps to 25.26% in 2023, then crashed by -34bps to 16.56% in 2024, then soared by 92bps to 31.73% in 2025.
  • Its FCF Margin stands at 31.73% for Q3 2025, versus 5.14% for Q2 2025 and 15.93% for Q1 2025.